Loading... Please wait...
App Store Download on the App Store Google Play GET IT ON Google Play

NLS Pharmaceutics AG (NLSP) Stock Price, News & Analysis

Currency in USD Disclaimer
Add to Alerts
Add to Watchlist
$0.22 -$0.02 (-9.63%)
$0.18
$0.22
$0.11
$1.53
Track all markets on TradingView

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -90.04
  • Piotroski Score 1.00
  • Grade N/A

Company brief: NLS Pharmaceutics AG (NLSP)

NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.

Price Target and Rating

  • $0.00
  • $0.00
  • $0.00
  • N/A
  • Sell
  • N/A
  • N/A

Profitability

  • -$0.32
  • -0.4
  • -0.4
  • -0.4
  • $-12,172,029

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Latest News of NLSP

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Log In

or
Continue with Google Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Sign Up With Email Address
or
Continue with Google Continue with Apple

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.